Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aquestive Therapeutics, Inc. - Common Stock (NQ:AQST)

4.090 +0.160 (+4.07%)
Streaming Delayed Price Updated: 12:54 PM EDT, Jul 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 304,347
Open 3.970
Bid (Size) 4.090 (6)
Ask (Size) 4.100 (20)
Prev. Close 3.930
Today's Range 3.970 - 4.099
52wk Range 2.120 - 5.800
Shares Outstanding 38,886,465
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics Provides International Expansion Update for Anaphylm™ (epinephrine) Sublingual Film
From Aquestive Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+11.4%
+11.4%
1 Month
+23.6%
+23.6%
3 Month
+44.3%
+44.3%
6 Month
+30.3%
+30.3%
1 Year
+7.1%
+7.1%

More News

Read More
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For May 12, 2025
Via Benzinga
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at the CFAAR Food Allergy Summit
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics Announces FDA Acceptance of New Drug Application and PDUFA Date for Anaphylm™ for the Treatment of Severe Allergic Reactions
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Uncovering Potential: Aquestive Therapeutics's Earnings Preview
Via Benzinga
Aquestive Therapeutics to Participate in Citizens Life Sciences Conference
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics to Report First Quarter 2025 Financial Results and Recent Business Highlights on May 12 and Host Conference Call on May 13 at 8:00 a.m. ET
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics Concludes FDA Application For Allergy Drug With Encouraging Pediatric Trial Data
Via Benzinga
Aquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm™ (epinephrine) Sublingual Film
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics Stock Dips After-Hours On Q4 Miss — Retail Eyes Silver Linings
Via Stocktwits
Curious about the stocks that are showing activity after the closing bell on Wednesday?
Via Chartmill
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics to Participate in Two Upcoming Conferences in March
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For March 5, 2025
Via Benzinga
Aquestive Therapeutics to Report Fourth Quarter 2024 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual Meeting
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Conference
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics Provides Business Update and Outlines Key 2025 Objectives
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Developer Of EpiPen Alternative Aquestive Stock Undervalued Despite Strong Clinical Data, Analyst Sees Huge Upside
Via Benzinga
Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual Film
From Aquestive Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Aquestive Therapeutics, Inc. - Common Stock publicly traded?
Yes, Aquestive Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Aquestive Therapeutics, Inc. - Common Stock trade on?
Aquestive Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Aquestive Therapeutics, Inc. - Common Stock?
The ticker symbol for Aquestive Therapeutics, Inc. - Common Stock is AQST on the Nasdaq Stock Market
What is the current price of Aquestive Therapeutics, Inc. - Common Stock?
The current price of Aquestive Therapeutics, Inc. - Common Stock is 4.090
When was Aquestive Therapeutics, Inc. - Common Stock last traded?
The last trade of Aquestive Therapeutics, Inc. - Common Stock was at 07/30/25 12:54 PM ET
What is the market capitalization of Aquestive Therapeutics, Inc. - Common Stock?
The market capitalization of Aquestive Therapeutics, Inc. - Common Stock is 159.05M
How many shares of Aquestive Therapeutics, Inc. - Common Stock are outstanding?
Aquestive Therapeutics, Inc. - Common Stock has 159M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.